MaxCyte(MXCT) Globenewswire·2025-06-11 06:00Core Viewpoint - MaxCyte and Ori Biotech have formed a strategic collaboration to enhance the efficiency, scalability, and productivity of cell therapy manufacturing by integrating their respective platforms, ExPERT™ and IRO® [1][4]. Group 1: Collaboration Details - The collaboration combines MaxCyte's ExPERT™ platform, known for its efficient transfection capabilities, with Ori's IRO platform, which automates cell therapy manufacturing [2][3]. - The initial evaluation will focus on optimizing the yield and manufacturing timelines of MaxCyte-engineered primary T cells using CD19 CAR expression via CRISPR knock-in [2][3]. Group 2: Technological Integration - MaxCyte's technology provides flexibility and efficiency in transfecting cells at a clinical scale, integrating well with various processes in cell therapy workflows [3]. - Ori's IRO platform enhances cell culture efficiency through automated fluid handling and customizable mixing, contributing to improved scalability [3]. Group 3: Leadership Insights - MaxCyte's CEO expressed excitement about the collaboration, emphasizing the commitment to improving manufacturing processes and accelerating the availability of cell therapies [4]. - Ori's CEO highlighted the partnership as a demonstration of their dedication to providing scalable solutions that address challenges in cell and gene therapy manufacturing [4]. Group 4: Industry Impact - The collaboration aims to enable therapy developers to adopt integrated solutions, thereby accelerating the transition from research to commercialization and increasing patient access to next-generation treatments [4].